In vitro metabolism of tegaserod in human liver and intestine: Assessment of drug interactions

Drug Metabolism and Disposition

Volumn 29, Issue 10, 2001, Pages 1269-1276

  Vickers, Alison E M ^a   Zollinger, Markus ^b   Dannecker, Robert ^b   Tynes, Ronald ^b   Heitz, Francis ^b   Fischer, Volker ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHOXYINDOLE 2 CARBOXYLIC ACID; COMPLEMENTARY DNA; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; DRUG METABOLITE; GLUCURONIC ACID; QUINIDINE; SEROTONIN AGONIST; TEGASEROD; UNCLASSIFIED DRUG;

ARTICLE; DRUG GLUCURONIDATION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG OXIDATION; DRUG TRANSFORMATION; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; INTESTINE; LIVER MICROSOME; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BIOTRANSFORMATION; DRUG INTERACTIONS; DRUG STABILITY; HUMANS; HYDROGEN-ION CONCENTRATION; INDOLES; INTESTINES; LIVER; MICROSOMES, LIVER; PHENACETIN; SEROTONIN AGONISTS; THEOPHYLLINE;

EID: 0034821488     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. 4 receptor agonist
2. Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s
3. Characterization of the cytochrome P-450 gene family responsible for the N-dealkylation of the ergot alkaloid CQA 206-291 in humans
4. Cisapride. Drug interactions of clinical significance
5. 5-HT4 receptors: An update. Serotoninergic neurons and 5-HT receptors in the CNS
6. Long QT syndrome during high-dose cisapride
7. 4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site
8. 4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists
9. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in viva and in vitro: Implications for proarrhythmic potential?
10. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation
11. Comparison of tegaserod (HTFg19) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart
12. Cardiac toxicity with cisapride
13. 4 agonist (SDZ HTF 919) and its main metabolite in conscious dogs: Effects on gastrointestinal motility and impaired gastric emptying
14. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A
15. The polymorphic cytochrome P4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron
16. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans
17. Syncopal episodes associated with cisapride and concurrent drugs
18. 4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine
19. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
20. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin
21. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
22. The effects of tegaserod (HTF919) on oesophageal acid exposure in gastro-oesophageal reflux disease
23. Tegaserod does not significantly affect the pharmacokinetics of dextromethorphan in healthy subjects
24. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine- metabolizing enzyme explains interactions of cyclosporine with other drugs
25. Bufuralol, dextromethorphan and debrisoquine as prototype substrates for human P450IID6
26. Tegaserod does not significantly affect the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
27. Relief of overall GI symptoms and abdominal pain and discomfort as outcome measures in a clinical trial of irritable bowel syndrome with HTF919
28. 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation
29. SDZ HTF 919 stimulates canine colonic motility and transit in vivo
30. The carbon monoxide-binding pigment of liver microsomes
31. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450IIE1
32. The properties of a new prokinetically active drug SDZ HTF 919
33. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome
34. Selective biotransformation of taxol to 6a-hydroxytoxol by human cytochrome P450 2C8
35. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily
36. Lack of drug-drug interaction between cervastatin and nifedipine
37. 4 receptor agonist
38. Rapid equilibrium partial and mixed-type inhibition
39. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450
40. - efflux from rat colonocytes
41. Specificity of substrate and inhibitor probes for human cytochromes P450 IA1 and IA2
42. Review article: Cardiac adverse effects of gastrointestinal prokinetics
43. Sites of biotransformation for the cyclosporin derivative SDZ IMM 125 using human liver and kidney slices and intestine
44. Cisapride and fatal arrhythmia
45. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: Role of cytochrome P450 3A in N-dealkylation and C-hydroxylation
46. Effect of gastric pH on plasma concentrations of tegaserod (HTF919) and its major metabolite in healthy subjects
47. Tegaserod coadministration does not alter theophylline pharmacokinetics in healthy subjects
48. Tegaserod (HTF919) does not decrease the effectivness of an oral contraceptive when coadministered to healthy female subjects